Cancer hypoxia correlates with therapeutic resistance and metastasis, suggesting that hypoxic adaptation is a critical survival advantage for cancer stem cells (CSCs). Hypoxic metabolism, however, may be a disadvantage in aerobic circulation as the extremely low incidence of metastasis-compared to the high circulating tumor-cell numbers (CTCs)-appears to suggest. As rare metastatic CSCs still survive, we searched for a mechanism that protects them from oxygen in circulation. CSCs form multicellular spheroids in vitro from virtually all cancers tested. We asked, therefore, whether cancers also form spheroids in vivo and whether circulating spheroids play a role in metastasis. We used metabolic, apoptotic and hypoxia assays, we measured aerobic barriers and calculated hypoxia vs. spheroid-size correlations. We detected metabolic/oxidative stress in spheroids, we found correlation between stem cell presence and hypoxia and we showed that the size of hypoxic spheroids is compatible with circulation. To detect spheroids in patients, we worked out a new light-scatter flow cytometry blood test and assayed 67 metastatic and control cases. We found in vivo spheroids with positive stem cell markers in cancer blood and they showed exclusive correlation with metastasis. In conclusion, our data suggest that metastatic success depends on CSC-association with in vivo spheroids. We propose that the mechanism involves a portable "micro-niche" in spheroids that may support CSC-survival/adaptation in circulation. The new assay may establish a potential early marker of metastatic progression.Malignant cells can enter circulation very early from most cancers (circulating tumor cells, CTCs), 1 yet metastases do not occur until much later (e.g., in pancreatic cancer).2 Enumeration of circulating cancer cells is part of the diagnostic arsenal, but not considered a direct marker of metastasis. Part of the reason is that the majority of cells in most cancers are not capable of seeding metastatic growth.3 Metastatic dissemination is the function of cancer stem cells (CSC), but the overwhelming majority of CTCs do not show stem cell features. 4 An assay to detect circulating CSCs, therefore, could serve as a marker for metastatic predisposition, 5 but it is not available in the oncology practice today.To develop such an assay we took advantage of a unique feature of CSCs, spheroid formation. Spheroids are small multicellular organoids formed in vitro by cells from most cancers. Spheroids are stabilized by cellular contacts that may also play a role in differentiation (e.g., the P19 model).6 With most cancers only a subset of cells can form spheroids and these cells share features with CSCs. 7,8 The same has been demonstrated with cell lines from a variety of tissues. 9 The almost universal potential for spheroids suggests that it may be a basic feature of CSCs akin to clonogenicity or growth in soft agar.We reasoned that if in vitro spheroid formation reflects an important biological function, it may also occur in vivo. To investigate thi...
Az elmúlt évtizedekben a daganatgyógyítás fejlődésének és eredményességének jeleként a lokális terápiás modalitások szerepe az áttétes betegségek ellátása során felértékelődött. A szerzők tudomása szerint a hazánkban első eredményes, koponyán kívüli sugársebészeti beavatkozást ismertetik. Az 58 éves férfi gyomoradenocarcinoma miatt műtéten, kemoterápián és mellékveseáttétek miatt metastatectomián esett át. Az első műtét után 4 évvel a követési komputertomográfi ás vizsgálat kétgócú és inoperábilisnak véleményezett peritonealis áttétképződést mutatott, a májszél, illetve a bal vese alatt, 2 cm-es átmérőkkel. Defi nitív ellátásként, egy ülésben 12 Gy dózisú stereotaxiás hasi sugársebészeti beavatkozást végeztek, cone-beam komputertomográfi ás ellenőrzés mellett, dinamikus ívbesugárzást, illetve 2-2 ívet alkalmazva. A kezelés 25 percig tartott, sem akut, sem késői mellékhatást nem észleltek. A kezelés után 3, illetve 7 hónappal elvégzett kontroll-komputertomográfi a teljes tumorregressziót igazolt. A szerzők megállapítják, hogy megfelelő technológia és gyakorlottság birtokában, nem gyorsan növekvő oligometasztázisok esetében a koponyán kívü-li stereotaxiás sugársebészeti ellátás biztonságos és hatékony alternatívája lehet a műtéti beavatkozásnak. Orv. Hetil., 2015, 156(39), 1593-1599. Kulcsszavak: oligometasztázis, stereotaxiás hasi sugársebészet, képvezérelt sugárterápia, intenzitásmodulált dinamikus ívbesugárzás Stereotactic radiosurgery of abdominal cancer metastases Report on the fi rst successful extracranial radiosurgical intervention in HungaryDue to the development and increasing effectiveness of novel cancer therapies, the role of local treatments in metastatic diseases have been increasing in the last decades. The aim of the authors was to present the fi rst successful extracranial stereotactic radiosurgical intervention in Hungary. A 58-year-old male patient with gastric adenocarcinoma underwent surgery and adjuvant chemotherapy. Later, surgical removal of suprarenal gland metastases and fi rst line chemotherapy were carried out. Four years after the fi rst surgery a follow up computed tomographic scan revealed bifocal peritoneal metastases caudally from the edge of the liver and the left kidney with diameters of 2 cm in size. Defi nitive stereotactic body radiosurgery of 12 Gy single dose was performed using cone beam computed tomography image guidance and intensity modulated arc therapy with two pairs of arcs. The total duration of the procedure was only 25 min and early or late side effects were not observed. Follow up computed tomography scans performed
The intensity modulated arc therapy with image guided radiotherapy proved to be a safe standard treatment mode in the daily routine in the institute of the authors. Late toxicity and local control rates need to be further examined.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.